Results 251 to 260 of about 114,148 (343)

Unusual Concurrent HBsAg and Anti-HBs Positivity in Chronic Hepatitis B with Compensated Cirrhosis. [PDF]

open access: yesEur J Case Rep Intern Med
Nguyen BTH   +6 more
europepmc   +1 more source

Immunomodulatory Fibrous Scaffold with Dual Enzyme‐Mimic Activities Prevents Postsurgical Tumor Recurrence

open access: yesAdvanced Science, EarlyView.
A MnOx nanozyme‐functionalized electrospun fibrous scaffold is developed for postoperative therapy by leveraging its intrinsic physicochemical and immunomodulatory properties. Integrating POD‐ and CAT‐like activities, the scaffold induces immunogenic cell death, alleviates hypoxia, and reverses immunosuppression, while simultaneously recruiting and ...
Xiaoyi Zhao   +9 more
wiley   +1 more source

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

open access: yesAdvanced Science, EarlyView.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li   +7 more
wiley   +1 more source

Microglial Membranes Wrapped Ultrasmall Medium‐Entropy Ru Single‐Atom Nanozyme: Enhanced Catalysis for Accelerating Inflammation/Redox Microenvironment Regulation in Intracerebral Hemorrhage

open access: yesAdvanced Science, EarlyView.
PtRhIr/Ru SAN@M nanozymes cross the blood–brain barrier and selectively accumulate in hemorrhagic brain regions. By mimicking multiple enzyme activities, they attenuate oxidative stress, modulate microglial polarization toward an anti‐inflammatory phenotype, inhibit ferroptosis, and promote neuronal repair.
Jiebo Li   +17 more
wiley   +1 more source

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao   +10 more
wiley   +1 more source

Fulminant hepatitis secondary to nivolumab in a patient with Hodgkin's Lymphoma after complete remission. [PDF]

open access: yesHematol Transfus Cell Ther
Negrelli Dos Santos AJ   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy